The stock of gene-sequencing equipment company Illumina is down more than 25% this ... this marks his first major test as he navigates the company’s post-Grail recovery.

Illumina lowers outlook due to China sales ban, to cut $100 million in costs Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced ...

But for biotech firm Illumina, a leading maker of gene-sequencing equipment ... Carl Icahn over the acquisition of cancer blood test maker Grail, growth has suffered and competition has intensified.

Illumina is still able to operate in China, as the Chinese government’s notice did not mention the reagents or consumables necessary to run the sequencing machines, the company noted.

HONG KONG] Hong Kong billionaire Li Ka-shing has raised Beijing’s ire by agreeing to sell its control over ports in Panama to ...

Pacific Biosciences' Q4'24 results were another disappointment ... PacBio's systems are being used in the real world and that long-read sequencing is growing. Major uncertainties in life sciences ...

In just the last 10 years, the cost per genome has been collapsing to the point that it is becoming a cheap test among the arsenal of tests available to medical professionals. By far the largest ...

1μl of total cellular RNA was used for sequencing library generation by NEBNext Ultra RNA Library Prep Kit for Illumina (NEB ... Data were analyzed through a two-tailed t-test. A probability of P < ...